Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2253024 | 0.85 | IL4I1 (0.55) | IL4I1MAOBLMNAALDH1A1KMT2A | |
| SCHEMBL6950065 | 0.84 | PTPN1 (0.54) | IL4I1MAOBLMNAPTPN1ALDH1A1 | |
| SCHEMBL3335985 | 0.84 | LMNA (0.59) | IL4I1MAOBLMNAALDH1A1MEN1 | |
| SCHEMBL6190226 | 0.82 | LMNA (0.69) | IL4I1MAOBLMNAALDH1A1MEN1 | |
| SCHEMBL14541452 | 0.81 | LMNA (0.67) | MAOBLMNAALDH1A1HPGDKMT2A | |
| SCHEMBL7665038 | 0.79 | PTPN1 (0.74) | PTPN1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL9660695 | 0.75 | MAOB (0.58) | IL4I1MAOBLMNAALDH1A1MEN1 | |
| SCHEMBL2087954 | 0.75 | MAOB (0.71) | MAOBNPC1RAB9A | |
| SCHEMBL8986618 | 0.75 | IL4I1 (0.55) | IL4I1MAOBMAPT | |
| SCHEMBL2094961 | 0.74 | TAAR1 (0.48) | CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0933354-B1 | CALCIUM RECEPTOR-ACTIVE COMPOUNDS | KYOWA HAKKO KIRIN CO LTD (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-7816408-B2 | Calcium receptor active compounds | NPS PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090176993-A1 | Calcium receptor active compounds | NPS PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-6939895-B2 | Calcium receptor-active compounds | NPS PHARMACEUTICALS, INC. (US) | 2005-09-06 | — | — | US | disclosed |
| US-6750255-B2 | SUCH AS (R)-N-(1-(1'-NAPHTHYL)ETHYL)-2-(2',5'-DICHOROPHENYL THIO)ETHYLAMINE; FOR STIMULATION OF SECRETION OF PARATHYROID HORMONE | NPS PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20030176485-A1 | Calcium receptor active compounds | NPS PHARMACEUTICALS, INC. | 2003-09-18 | — | — | US | disclosed |
| US-20030144526-A1 | Calcium receptor-active compounds | NPS PHARMACEUTICALS, INC. | 2003-07-31 | — | — | US | disclosed |
| US-20020107406-A1 | Calcium receptor-active compounds | NPS PHARMACEUTICALS, INC. (US) | 2002-08-08 | — | — | US | disclosed |
| US-6362231-B1 | MODULATOR OF PARATHYROID HORMONE; OSTEOPOROSIS | NPS PHARMACEUTICALS, INC. | 2002-03-26 | — | — | US | disclosed |
| EP-0933354-A1 | CALCIUM RECEPTOR-ACTIVE COMPOUNDS | KIRIN BEER KABUSHIKI KAISHA (JP) | 1999-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144526-A1 | Calcium receptor-active compounds | CASR, CALCR, CNR1 | IL4I1 2446/4885MAOB 3108/4885LMNA 4615/4885 |
| US-20090176993-A1 | Calcium receptor active compounds | CASR, CALCR, CACNA1E | IL4I1 2498/4885MAOB 3612/4885LMNA 4836/4885 |
| US-20030176485-A1 | Calcium receptor active compounds | CASR, CNR1, CALCR | IL4I1 2504/4885MAOB 3140/4885LMNA 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.